Intro
Preface
Contents
About the Editors
Part I: Introduction
Chapter 1: Introduction: An Overview of Host-Directed Therapies for Tuberculosis
Host-Directed Therapy: Purpose and History
The Antibiotic Era
Host Response to Mtb
The Inflammatory Response
Immunosupression
Immunometabolism
The Modern HDT Clinical Pipeline
Conclusion
References
Part II: Targeting Immunometabolism
Chapter 2: Sirtuin Deacetylases: Linking Mycobacterial Infection and Host Metabolism
Introduction
The Sirtuin Family
Sirtuins, Mitochondria, and Inflammation

LXR and Host Defense During Mtb Infection
Conclusions
References
Part III: Enhancing Anti-mycobacterial Mechanisms
Chapter 6: Autophagy as a Target for Host-Directed Therapy Against Tuberculosis
Introduction
Antibiotic Resistance in TB and the Need for Host-Directed Therapy
Autophagy: The Conserved Cellular Process of Degradation
Autophagy as a Defense Mechanism Against Mycobacterium tuberculosis
Regulation of Autophagy During Mycobacterium tuberculosis Infection
Modulation of Autophagy as Preferred Mechanisms for Survival by Mycobacteria

Subversion of Autophagy by Mtb Via Targeting RNA Metabolism
Autophagy Modulators as Therapeutic Candidates Against Tuberculosis
Future Perspective
References
Chapter 7: Metformin: A Leading HDT Candidate for TB
Introduction
Mechanistic Targets of Metformin
Studies Demonstrating Metformin's Anti-TB Properties
Can Metformin Rewire Fibrotic Resolution in TB?
Safety and Drug-Drug Interactions During Metformin Usage in TB Patients
Conclusions
References
Chapter 8: Statins as Host-Directed Therapy for Tuberculosis
Introduction